Detection of Circulating Anti-p53 Antibodies in Esophageal Cancer Patients

Journal of Nippon Medical School

Volumn 67, Issue 2, 2000, Pages 110-117

  Hagiwara, Nobutoshi ^a   Onda, Masahiko ^a   Miyashita, Masao ^a   Sasajima, Koji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

carcinoma; esophagus; p53; serum anti p53 antibody; tumor marker

Indexed keywords

CANCER ANTIBODY; PROTEIN P53; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; AGED; ARTICLE; BASAL CELL CARCINOMA; BLOOD; COMPARATIVE STUDY; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA, BASOSQUAMOUS; CARCINOMA, MUCOEPIDERMOID; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034169271     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.67.110     Document Type: Article

References (58)

1. Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184–197.
2. Pisani P, Parkin DM, Bray F, Ferlay J: Estimate of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18–29.
3. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T: CYFRA 21 – 1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997; 79: 1647–1655.
4. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S: CYFRA 21 – 1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998; 11: 31–39.
5. Harris CC, Hollstein M: Clinical implications of the p53 tumor–suppressor gene. N Engl J Med 1993; 329: 1318–1327.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991; 253: 49–53.
7. Bosari S, Viale G: The clinical significance of p53 abberations in human tumours. Virchows Arch 1995; 427: 229–241.
8. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991; 351: 453–456.
9. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collis FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–708.
10. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutatins for transformation by p53 produce a gene product than that forms an hsc 70–p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531–539.
11. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T: Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma: Virchows Arch A Pathol Anat Histopathol 1993; 422: 271–276.
12. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, Suthar TP, Balar DB: Clinical significance of p53, nm 23, and bcl–2 in T3–4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol 1997; 65: 111–116.
13. Chanvitan A, Nekarda H, Casson AG: Prognositic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcionoma in Thailand. Int J Cancer 1995; 63: 381–386.
14. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998; 4: 1469–1474.
15. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G: Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758–764.
16. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42–48.
17. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: Accumulation of p53 tumour suppressor gene protein-an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84: 845–855.
18. Starzynska T, Bromley M, Ghosh A, Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558–562.
19. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7–18.
20. Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS: p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994; 54: 4342–4346.
21. Parenti AR, Rugge M, Frizzeraa E, Roul A, Noventa F, Ancona E, Ninfo V: p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pahtol 1995; 19: 1418–1422.
22. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is independent upon p53 HSP 70 complexes in breast cancer. Proc Natl Acad Sci USA 1992; 89: 3439–3442.
23. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168–4174.
24. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP: p53 antibodies in patients with various types ofcancer: assay, identification, and characterization. Clin Cancer Res 1995; 1: 1463–9.
25. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris CC: Anti–p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995; 87: 1400–1407.
26. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403–408.
27. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P: Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987; 39: 185–189.
28. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380–6384.
29. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS: Prevelence of serum antibodies against the p53 tumor suppressor gene protein in various cancer. Int J Cancer 1994; 58: 480–487.
30. Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H: Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70: 1031–1034.
31. Preudhomme C, Lubin R, Lepelley P, Vanrumbeke M, Fenaux P: Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1994; 8: 1589–1591.
32. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, Vainio H: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995; 64: 176–181.
33. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G: Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 1998; 77: 1848–51.
34. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK: Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998; 4: 2147–2152.
35. Cawley HM, Meltzer SJ, De Benedetti VM, Hollstein MC, Muehlbauer KR, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrell J, Salabes A, Bartsch H, Trivers GE: Anti-p53 antibodies in patients with Barrett–s esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115: 19–27.
36. von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N, Trivers GE: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996; 56: 4917–4921.
37. Shimada H, Arima M, Nakajima K, Koide Y, Okazumi S, Matsubara H, Miyazawa Y, Takeda A, Hayashi H, Yoshida T, Ochiai T, Isono K: Detection of serum p53 antibodies in mucosal esophageal cancer and negative conversion after treatment. Am J Gastroenterol 1998; 93: 1388–1389.
38. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, Kommerell B, Zentgraf H, Galle PR: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 1993; 18: 559–565.
39. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994; 69: 1115–1119.
40. Green JA, Robertson LJ, Campbell IR, Jenkins J: Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995; 19: 151–155.
41. Komiya T, Hirashima T, Takada M, Masuda N, Yasumitsu T, Nakagawa K, Hosono Y, Kikui M, Tsuji S, Fukuoka M, Kawase I: Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997; 17: 3721–3724.
42. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, Sugimachi K: Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85: 302–308.
43. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992; 70: 524–526.
44. Dong X, Hamilton KJ, Satoh M, Wang J, Reeves WH: Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV 40 large T antigen. J Exp Med 1994; 179: 1243–1252.
45. Milner J: DNA damage, p53 and anticancer therapies. Nat Med 1995; 1: 879–880.
46. Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997; 40: 356–361.
47. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69: 943–946.
48. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T: Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621–622.
49. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D: Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997; 23: 30–35.
50. Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matusmura Y: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999; 72: 94–98.
51. Labrecque S, Naor N, Thomson D, Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53: 3468–3471.
52. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G: p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993; 169: 426–430.
53. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, Nesland JM: Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993; 169: 21–26.
54. Nuorva K, Soini Y, Kamel D, Autio-Harmainen H, Risteli L, Risteli J, Vahakangas K, Paakko P: Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 1993; 142: 725–732.
55. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107: 1012–1018.
56. Symmans PJ, Linehan JM, Brito MJ, Filipe MI: p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994; 173: 221–226.
57. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, Harris CC: p53 mutations and protein accumulation during multistage human esophageal carcinoma. Cancer Res 1992; 52: 6092–6097.
58. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE: Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773–776.